PD-1 and PD-L1 Expression in Endometrial Cancer: A Systematic Review of the Literature
Journal of Clinical Medicine · 10.01.2025 · 14 (2) · 401
DOI: 10.3390/jcm14020401 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 10.01.2025. Verfasst von Orazio De Tommasi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Gynecology and Obstetrics, Department of Women and Children's Health, University of Padua, 35122 Padua, Italy. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Cancer immunotherapy through the use of PD-1/PD-L1 inhibitors have shown significant promise in endometrial carcinoma (EC), particularly in tumors with microsatellite instability (MSI) or mismatch repair deficiency (dMMR), present in approximately 30% of cases. This review evaluated PD-L1 and PD-1 expression as potential biomarkers for immunotherapy response in EC, focusing on their relationship with MSI status.
Methods
A systematic review, adhering to PRISMA guidelines, analyzed studies from MEDLINE and Embase until February 2023 on PD-1/PD-L1 expression in EC stratified by MSI status, including diverse study designs but excluding conference abstracts, with independent screening, data extraction, and additional reference checks to ensure comprehensive coverage.
Results
A systematic analysis of 10 studies found that PD-L1 expression was more frequently expressed in MSI tumors (49%) compared to microsatellite-stable tumors (MSS) (33.5%), while PD-1 was expressed in 58% of MSI cases and 48% of MSS cases. Despite these findings, the prognostic value of PD-L1/PD-1 remains uncertain, with conflicting results regarding their association with survival outcomes. PD-L1 expression varied across molecular subtypes, being highest in POLE-mutated tumors (76.56%) and serous carcinomas (73%). Differences in PD-L1 expression between primary and metastatic sites were also noted, complicating its use as a biomarker.
Conclusions
The assessment of PD-L1 expression in EC could represent a valuable option for selecting patients who may benefit from immune checkpoint inhibitors (ICI), including those in the MSS cohort, thereby ensuring a more tailored and personalized treatment strategy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Unit of Gynecology and Obstetrics, Department of Women and Children's Health, University of Padua, 35122 Padua, Italy.
- Department of General Surgery and Medical Surgical Specialties, University of Catania, 95123 Catania, Italy.
- Department of Oncology, Ordine Mauriziano Hospital, University of Turin, 10124 Turin, Italy.
- Istituto Oncologico Veneto IOV-IRCCS, 35128 Padova, Italy.
ORCID-Profile: Orazio De Tommasi, Matteo Marchetti, Sofia Bigardi, Giosuè Giordano Incognito, Giulia Tasca, Carlo Saccardi, Roberto Tozzi
Zitieren
APA
De Tommasi, O., Marchetti, M., Tripepi, M., Bigardi, S., Incognito, G. G., Tuninetti, V., Facchetti, E., Tasca, G., Noventa, M., Saccardi, C., Tozzi, R., & Spagnol, G. (2025). PD-1 and PD-L1 Expression in Endometrial Cancer: A Systematic Review of the Literature. Journal of Clinical Medicine, 14(2), 401. https://doi.org/10.3390/jcm14020401
Vancouver
De Tommasi O, Marchetti M, Tripepi M, Bigardi S, Incognito GG, Tuninetti V, et al. PD-1 and PD-L1 Expression in Endometrial Cancer: A Systematic Review of the Literature. Journal of Clinical Medicine. 2025;14(2):401. doi:10.3390/jcm14020401
BibTeX
@article{DeTommasi2025,
author = {De Tommasi, Orazio and Marchetti, Matteo and Tripepi, Marta and Bigardi, Sofia and Incognito, Giosuè Giordano and Tuninetti, Valentina and Facchetti, Emma and Tasca, Giulia and Noventa, Marco and Saccardi, Carlo and Tozzi, Roberto and Spagnol, Giulia},
title = {PD-1 and PD-L1 Expression in Endometrial Cancer: A Systematic Review of the Literature},
journal = {Journal of Clinical Medicine},
year = {2025},
volume = {14},
number = {2},
pages = {401},
doi = {10.3390/jcm14020401}
}
EUVIMED